M J Morris

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. doi request reprint Monitoring the clinical outcomes in advanced prostate cancer: what imaging modalities and other markers are reliable?
    Michael J Morris
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Semin Oncol 40:375-92. 2013
  2. pmc A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer
    M J Morris
    Department of Medicine, Genitourinary Oncology Service, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, NY 10065, USA
    Ann Oncol 23:2714-9. 2012
  3. pmc Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer
    Elizabeth R Dennis
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Clin Oncol 30:519-24. 2012
  4. pmc Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy
    Michael J Morris
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer, New York, New York 10021, USA
    Clin Cancer Res 11:3210-6. 2005
  5. ncbi request reprint Targeting osseous metastases: rationale and development of radio-immunotherapy for prostate cancer
    Michael J Morris
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 444, New York, NY 10021, USA
    Curr Urol Rep 6:163-70. 2005
  6. ncbi request reprint Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer
    Michael J Morris
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Cancer Res 11:7454-61. 2005
  7. pmc Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer
    Michael J Morris
    Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Clin Oncol 27:2436-42. 2009
  8. ncbi request reprint Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumors
    Michael J Morris
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Cancer Res 13:2707-13. 2007
  9. pmc Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer
    Michael J Morris
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Eur Urol 56:237-44. 2009
  10. ncbi request reprint Safety and biologic activity of intravenous BCL-2 antisense oligonucleotide (G3139) and taxane chemotherapy in patients with advanced cancer
    Michael J Morris
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Appl Immunohistochem Mol Morphol 13:6-13. 2005

Research Grants

  1. Radioimmunotherapy for Prostate Cancer
    Michael Morris; Fiscal Year: 2007

Detail Information

Publications45

  1. doi request reprint Monitoring the clinical outcomes in advanced prostate cancer: what imaging modalities and other markers are reliable?
    Michael J Morris
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Semin Oncol 40:375-92. 2013
    ..In this review, we critically assess each of these classes of novel biomarkers--imaging, CTC, and PROs--in regard to the quality of data supporting their use to monitor clinical outcomes in advanced prostate cancer...
  2. pmc A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer
    M J Morris
    Department of Medicine, Genitourinary Oncology Service, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, NY 10065, USA
    Ann Oncol 23:2714-9. 2012
    ....
  3. pmc Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer
    Elizabeth R Dennis
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Clin Oncol 30:519-24. 2012
    ..Prior studies have shown the prognostic value of a baseline BSI. This study tested whether treatment-related changes in BSI are prognostic for survival and compared BSI to prostate-specific antigen (PSA) as an outcome measure...
  4. pmc Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy
    Michael J Morris
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer, New York, New York 10021, USA
    Clin Cancer Res 11:3210-6. 2005
    ..We tested the hypothesis that serial fluorodeoxyglucose positron emission tomography (FDG-PET) scans can serve as an outcome measure for patients with castrate metastatic prostate cancer treated with antimicrotubule chemotherapy...
  5. ncbi request reprint Targeting osseous metastases: rationale and development of radio-immunotherapy for prostate cancer
    Michael J Morris
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 444, New York, NY 10021, USA
    Curr Urol Rep 6:163-70. 2005
    ..In this article, we review the rationale behind this approach, the targets being explored, the radiation sources available, and the antibodies currently under clinical development...
  6. ncbi request reprint Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer
    Michael J Morris
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Cancer Res 11:7454-61. 2005
    ..The relationship among dose, safety, pharmacokinetics, and antibody-dependent cellular cytotoxicity (ADCC) activation for unlabeled J591 has not been explored...
  7. pmc Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer
    Michael J Morris
    Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Clin Oncol 27:2436-42. 2009
    ..To build on this strategy and fully integrate a repetitively dosed bone-seeking radiopharmaceutical into a contemporary chemotherapy regimen, we conducted a phase I study of docetaxel and samarium-153 ((153)Sm) lexidronam...
  8. ncbi request reprint Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumors
    Michael J Morris
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Cancer Res 13:2707-13. 2007
    ..This phase I trial tested the hypothesis that J591 could be used as a vascular targeting platform for patients with nonprostate solid tumors...
  9. pmc Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer
    Michael J Morris
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Eur Urol 56:237-44. 2009
    ..Growth of selected castration-resistant prostate cancer (CRPC) cell lines and animal models can be repressed by reexposure to androgens. Low doses of androgens, however, can stimulate tumor growth...
  10. ncbi request reprint Safety and biologic activity of intravenous BCL-2 antisense oligonucleotide (G3139) and taxane chemotherapy in patients with advanced cancer
    Michael J Morris
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Appl Immunohistochem Mol Morphol 13:6-13. 2005
    ..These data support the dose selection of ongoing phase 2 studies of G3139 at 7 mg/kg/d and docetaxel 75 mg/m2...
  11. ncbi request reprint High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma
    Michael J Morris
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 100:1868-75. 2004
    ..Pulse-dosed calcitriol and dexamethasone may maximize tolerability and efficacy. The authors examined the toxicity of pulse-dosed calcitriol with zoledronate and with the addition of dexamethasone at the time of disease progression...
  12. ncbi request reprint Novel strategies and therapeutics for the treatment of prostate carcinoma
    M J Morris
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 89:1329-48. 2000
    ..Angiogenesis and tumor invasion also have been targeted, as have cell cycling and signal transduction. Strategies promoting apoptosis and augmenting differentiation are also under study...
  13. ncbi request reprint Targeting osseous metastases: rationale and development of radio-immunotherapy for prostate cancer
    Michael J Morris
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 444, New York, NY 10021, USA
    Curr Oncol Rep 6:222-9. 2004
    ..In this article, we review the rationale behind this approach, the targets being explored, the radiation sources available, and the antibodies currently under clinical development...
  14. ncbi request reprint Novel therapies for the treatment of prostate cancer: current clinical trials and development strategies
    Michael J Morris
    Department of Genitourinary Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 444, New York, NY 10021, USA
    Surg Oncol 11:13-23. 2002
    ..Investigators use a clinical states model as a framework for matching specific agents with the needs of the treatment population and the biology of the tumor at any given point in the natural history of the disease...
  15. ncbi request reprint Optimizing targeted therapy and developing novel outcome measures for patients with advanced prostate cancer at Memorial Sloan-Kettering Cancer Center
    Michael J Morris
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 444, 10021, New York, NY, USA
    Crit Rev Oncol Hematol 46:S21-31. 2003
    ..High-throughput preclinical assays of gene expression are being developed to enhance selection of drug sequences and combinations for clinical testing...
  16. ncbi request reprint Clinical approaches to osseous metastases in prostate cancer
    Michael J Morris
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Oncologist 8:161-73. 2003
    ..Treatments directed against bone disease have the potential both to palliate pain and to increase survival...
  17. ncbi request reprint Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castration
    O Smaletz
    Department of Medicine, Division of Solid Tumor, Memorial Sloan Kettering Cancer Center, Joan and Sanford I Weill Medical College of Cornell University, New York, NY 10021, USA
    Ann Oncol 14:1518-24. 2003
    ..We conducted a dose-escalation study to determine a safe dose of BMS-247550 to combine with EMP in patients with metastatic prostate cancer...
  18. ncbi request reprint A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancer
    Michael J Morris
    Department of Medicine Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 178:2378-83; discussion 2383-4. 2007
    ..We defined the antitumor effects of bortezomib alone and in combination with prednisone in patients with progressive, castration resistant metastatic prostate cancer...
  19. ncbi request reprint HER-2 profiling and targeting in prostate carcinoma
    Michael J Morris
    Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 94:980-6. 2002
    ..This study explored the feasibility of molecular profiling to determine the correlation between HER-2 expression, hormonal sensitivity, and the antitumor effects of trastuzumab and paclitaxel in patients with prostate carcinoma...
  20. ncbi request reprint Castration resistant, taxane naïve metastatic prostate cancer: current clinical approaches and future directions
    Gretchen A Gignac
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 178:S30-5. 2007
    ..We focused on the current management and novel investigational strategies for the chemonaïve patient population with castration resistant metastatic disease...
  21. pmc Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer
    Daniel C Danila
    Department of Medicine, Joan and Sanford E Weill College of Medicine of Cornell University, Ithaca, NY, USA
    J Clin Oncol 28:1496-501. 2010
    ..This trial evaluated the efficacy and safety of AA in combination with prednisone to reduce the symptoms of secondary hyperaldosteronism that can occur with AA monotherapy...
  22. pmc Antibody mass escalation study in patients with castration-resistant prostate cancer using 111In-J591: lesion detectability and dosimetric projections for 90Y radioimmunotherapy
    Neeta Pandit-Taskar
    Nuclear Medicine Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 49:1066-74. 2008
    ..An analysis was performed to assess lesion detectability by (111)In-J591 gamma-camera imaging compared with standard imaging methods and the effect of increasing antibody mass on lesion detectability, biodistribution, and dosimetry...
  23. pmc Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer
    Dana Rathkopf
    Department of Medicine, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 26:2959-65. 2008
    ..We evaluated rapid androgen cycling in combination with docetaxel for men with progressive noncastrate prostate cancers...
  24. pmc Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study
    Howard I Scher
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Lancet 375:1437-46. 2010
    ..Because growth of castration-resistant prostate cancer is dependent on continued androgen-receptor signalling, we assessed the antitumour activity and safety of MDV3100 in men with this disease...
  25. ncbi request reprint Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials
    Mark T Fleming
    Department of Medicine, Sidney Kimmel Center for Prostate and Urologic Cancer, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Nat Clin Pract Oncol 3:658-67. 2006
    ..It is important to recognize that there are a range of clinical benefits to patients that can improve the quality and possibly the duration of survival, independent of PSA...
  26. doi request reprint Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer
    Kouta Ito
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Intern Med 152:621-9. 2010
    ..Objective: To assess the cost-effectiveness of measuring bone mineral density (BMD) before initiating ADT followed by alendronate therapy in men with localized prostate cancer...
  27. pmc Prostate cancer clinical trial end points: "RECIST"ing a step backwards
    Howard I Scher
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 11:5223-32. 2005
    ..To relate clinical issues to the clinical manifestations of prostate cancers across disease states using the eligibility and outcome criteria defined by Response Evaluation Criteria in Solid Tumors (RECIST)...
  28. ncbi request reprint Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer
    Michael J Morris
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 8:679-83. 2002
    ..To evaluate the safety and pharmacokinetics of BCL-2 antisense oligonucleotide (G3139) administered by prolonged i.v. infusion in patients with advanced cancer...
  29. ncbi request reprint Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer
    Michael J Morris
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Urology 59:913-8. 2002
    ....
  30. pmc Pharmacokinetic assessment of the uptake of 16beta-18F-fluoro-5alpha-dihydrotestosterone (FDHT) in prostate tumors as measured by PET
    Bradley J Beattie
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 51:183-92. 2010
    ....
  31. pmc Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer
    David B Solit
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Cancer Res 13:1775-82. 2007
    ..To define the maximum tolerated dose (MTD), toxicities, and pharmacokinetics of 17-allylamino-17-demethoxygeldanamycin (17-AAG) when administered using continuous and intermittent dosing schedules...
  32. pmc Assessing outcomes in prostate cancer clinical trials: a twenty-first century tower of Babel
    Gretchen A Gignac
    Department of Medicine, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 113:966-74. 2008
    ..PFS, however, is vulnerable to inter-study design variability. The authors sought to identify and quantify this variability and the resultant error in PFS across prostate cancer clinical trials...
  33. pmc Novel tracers and their development for the imaging of metastatic prostate cancer
    Andrea B Apolo
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Nucl Med 49:2031-41. 2008
    ..Hence, although many promising agents are available for testing, such studies would benefit from closer collaboration between those in the fields of medical oncology and nuclear medicine...
  34. ncbi request reprint Fatal respiratory failure associated with treatment of prostate cancer using docetaxel and estramustine
    Michael J Morris
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Cornell University Weill Medical College, New York, New York, USA
    Urology 60:1111. 2002
    ..We recommend that patients receiving weekly docetaxel, with or without estramustine, have frequent treatment breaks and be evaluated with computed tomography of the chest every 8 weeks...
  35. pmc Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research
    Michael J Morris
    Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Clin Genitourin Cancer 7:51-7. 2009
    ..This is the first report of the Prostate Cancer Clinical Trials Consortium (PCCTC)...
  36. pmc Germline BRCA mutations denote a clinicopathologic subset of prostate cancer
    David J Gallagher
    Clinical Genetics Service, Department of Medicine, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Cancer Res 16:2115-21. 2010
    ..Increased prostate cancer risk has been reported for BRCA mutation carriers, but BRCA-associated clinicopathologic features have not been clearly defined...
  37. ncbi request reprint Cardiopulmonary exercise test interpretation using age-matched controls to evaluate exertional dyspnea
    Joshua M Sill
    Pulmonary Disease Critical Care Medicine Service, Department of Medicine, Brooke Army Medical Center, 3851 Roger Brooke Road, Fort Sam Houston, TX 78234 6200, USA
    Mil Med 174:1177-82. 2009
    ..This study evaluated interpretation of maximal CPET in a young adult cohort with known pulmonary disorders using published reference values compared to age-matched normal controls...
  38. pmc Imaging therapeutic response in human bone marrow using rapid whole-body MRI
    Douglas Ballon
    Department of Radiology, Weill Medical College of Cornell University, New York, New York 10021, USA
    Magn Reson Med 52:1234-8. 2004
    ..Examples presented include the evaluation of therapeutic response in bone marrow during cytotoxic therapy for leukemia and metastatic prostate cancer and during cytokine administration for marrow mobilization prior to stem cell harvest...
  39. ncbi request reprint Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases
    Paul Mathew
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 13:5816-24. 2007
    ....
  40. ncbi request reprint (11)C-acetate PET imaging in prostate cancer
    Michael J Morris
    Eur J Nucl Med Mol Imaging 34:181-4. 2007
  41. ncbi request reprint Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy
    David B Agus
    Cedars Sinai Prostate Cancer Center, Los Angeles, CA 90048, USA
    J Clin Oncol 25:675-81. 2007
    ..The aim of this single-arm phase II clinical study was to assess the efficacy and safety of single-agent pertuzumab in castration-resistant prostate cancer (CRPC) patients who had experienced progression after prior chemotherapy...
  42. ncbi request reprint Innovations and challenges in prostate cancer: summary statement for the 6th Cambridge Conference
    Philip W Kantoff
    Lank Center for Genitourinary Oncology, Boston, Massachusetts, USA
    J Urol 178:S5-8; quiz S4. 2007
  43. doi request reprint Expression of prostate-specific membrane antigen in renal cortical tumors
    Hikmat A Al-Ahmadie
    Department of Pathology, University of Chicago, Chicago, IL, USA
    Mod Pathol 21:727-32. 2008
    ....
  44. ncbi request reprint Progressive vocal cord dysfunction subsequent to a chlorine gas exposure
    Patrick F Allan
    Pulmonary Medicine Flight, Wilford Hall Medical Center, Lackland AFB, San Antonio, Texas, USA
    J Voice 20:291-6. 2006
    ..This article constitutes the first case of a single antecedent chlorine exposure inducing progressive vocal cord dysfunction...
  45. ncbi request reprint A phenolate-induced trans influence: crystallographic evidence for unusual asymmetric coordination of an alpha-diimine in ternary complexes of iron(III) possessing biologically relevant hetero-donor N-centered tripodal ligands
    Musa S Shongwe
    Department of Chemistry, College of Science, Sultan Qaboos University, P O Box 36, Al Khod 123, Muscat, Sultanate of Oman
    Inorg Chem 44:3070-9. 2005
    ....

Research Grants1

  1. Radioimmunotherapy for Prostate Cancer
    Michael Morris; Fiscal Year: 2007
    ..The acquisition of these skills combined with the completion of the research plan will allow the candidate to pursue such research independently. ..